These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18558893)

  • 1. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria.
    Dietze PM; Cvetkovski S; Barratt MJ; Clemens S
    Med J Aust; 2008 Jun; 188(12):709-11. PubMed ID: 18558893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in gamma-hydroxybutyrate-related harms based on ambulance attendances from 2012 to 2018 in Victoria, Australia.
    Arunogiri S; Moayeri F; Crossin R; Killian JJ; Smith K; Scott D; Lubman DI
    Addiction; 2020 Mar; 115(3):473-479. PubMed ID: 31618793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse outcomes of GHB use: Analysis of ambulance attendances in metropolitan and regional Victoria.
    Ogeil RP; Faulkner A; Beard N; Killian JJ; Arunogiri S; Phan V; Wilson J; Smith K; Lubman DI; Scott D
    Int J Drug Policy; 2023 Jan; 111():103932. PubMed ID: 36527909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospital in the field: prehospital management of GHB intoxication by medical assistance teams.
    Dutch MJ; Austin KB
    Prehosp Disaster Med; 2012 Oct; 27(5):463-7. PubMed ID: 22809488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence and characteristics of volatile substance use related ambulance attendances in metropolitan Melbourne, Australia.
    Cvetkovski S; Dietze P
    Soc Sci Med; 2008 Feb; 66(3):776-83. PubMed ID: 18023515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of non-fatal opioid overdoses attended by ambulance services in Australia.
    Dietze P; Jolley D; Cvetkovski S; Cantwell K; Jacobs I; Indig D
    Aust N Z J Public Health; 2004 Dec; 28(6):569-75. PubMed ID: 15707208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregabalin misuse-related ambulance attendances in Victoria, 2012-2017: characteristics of patients and attendances.
    Crossin R; Scott D; Arunogiri S; Smith K; Dietze PM; Lubman DI
    Med J Aust; 2019 Feb; 210(2):75-79. PubMed ID: 30712302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Victoria, Australia from 2013 to 2018.
    Nielsen S; Crossin R; Middleton M; Lam T; Wilson J; Scott D; Martin C; Smith K; Lubman D
    Addiction; 2020 Jun; 115(6):1075-1087. PubMed ID: 31742765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances.
    Heilbronn C; Lloyd B; McElwee P; Eade A; Lubman DI
    Drug Alcohol Rev; 2013 Jul; 32(4):405-11. PubMed ID: 23350582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The characteristics of acute non-fatal medication-related events attended by ambulance services in the Melbourne Metropolitan Area 1998-2002.
    Hutton J; Dent A; Buykx P; Burgess S; Flander L; Dietze P
    Drug Alcohol Rev; 2010 Jan; 29(1):53-8. PubMed ID: 20078683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggression and violence at ambulance attendances where alcohol, illicit and/or pharmaceutical drugs were recorded: A 5-year study of ambulance records in Victoria, Australia.
    Coomber K; Curtis A; Vandenberg B; Miller PG; Heilbronn C; Matthews S; Smith K; Wilson J; Moayeri F; Mayshak R; Lubman DI; Scott D
    Drug Alcohol Depend; 2019 Dec; 205():107685. PubMed ID: 31704380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time-series analysis.
    McAuley A; Bouttell J; Barnsdale L; Mackay D; Lewsey J; Hunter C; Robinson M
    Addiction; 2017 Feb; 112(2):301-308. PubMed ID: 27614084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methadone- and buprenorphine-related ambulance attendances: a population-based indicator of adverse events.
    Nielsen S; Dietze P; Cantwell K; Lee N; Taylor D
    J Subst Abuse Treat; 2008 Dec; 35(4):457-61. PubMed ID: 18295435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma-hydroxybutyrate: a 30 month emergency department review.
    Munir VL; Hutton JE; Harney JP; Buykx P; Weiland TJ; Dent AW
    Emerg Med Australas; 2008 Dec; 20(6):521-30. PubMed ID: 19125832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends over time in characteristics of pharmaceutical drug-related ambulance attendances in Melbourne.
    Lloyd BK; McElwee PR
    Drug Alcohol Rev; 2011 May; 30(3):271-80. PubMed ID: 21545557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in cannabis-related ambulance presentations from 2000 to 2013 in Melbourne, Australia.
    Kaar SJ; Gao CX; Lloyd B; Smith K; Lubman DI
    Drug Alcohol Depend; 2015 Oct; 155():24-30. PubMed ID: 26361711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal differences in γ-hydroxybutyrate overdoses involving injecting drug users versus recreational drug users in Helsinki: a retrospective study.
    Boyd JJ; Kuisma MJ; Randell TT
    Scand J Trauma Resusc Emerg Med; 2012 Feb; 20():7. PubMed ID: 22296777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute harms associated with inhalant misuse: Co-morbidities and trends relative to age and gender among ambulance attendees.
    Crossin R; Scott D; Witt KG; Duncan JR; Smith K; Lubman DI
    Drug Alcohol Depend; 2018 Sep; 190():46-53. PubMed ID: 29981942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent trends in heroin and pharmaceutical opioid-related harms in Victoria, Australia up to 2018.
    Lam T; Kuhn L; Hayman J; Middleton M; Wilson J; Scott D; Lubman DI; Smith K; Nielsen S
    Addiction; 2020 Feb; 115(2):261-269. PubMed ID: 31465131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-related ambulance attendances during the first 2 years of the COVID-19 pandemic in Victoria, Australia.
    McGrath M; Stare M; Chua P; Ogeil R; Nehme Z; Scott D; Lubman DI
    Addiction; 2024 Feb; 119(2):348-355. PubMed ID: 37816493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.